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com (C. Pessoa).(4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT) belongs to the phenstatin family. This
compound has been studied due to its potent cytotoxicity and ability to inhibit tubulin assembly. The
present study aimed to evaluate the mutagenic potential of PHT in human lymphocytes. PHT displayed
cytotoxicity in human lymphocytes with an IC50 value of 5.68 lM, and therefore, concentrations of
0.25, 0.5, 1.0, 2.0, and 4.0 lMwere used for all protocols. The alkaline comet assay and chromosome aber-
ration (CA) analysis were performed in different phases of the cell cycle (G1, G1/S, transition, and G2), to
evaluate the DNA-damaging and clastogenic effects of PHT, respectively. CA analysis was carried out in
the presence or absence of colchicine to evaluate the action of PHT in the mitotic phase. PHT was cyto-
toxic and signiﬁcantly reduced the mitotic index with drug exposure in all phases of cell cycle. Interest-
ingly, it induced an increase in mitotic index in experimental protocols without colchicine, corroborating
its action as an antitubulin agent. It also induced DNA damage and was clastogenic with drug exposure in
all phases of the cell cycle, in the presence or absence of colchicine. In conclusion, PHT induces DNA dam-
age and exerts clastogenic effects in human lymphocytes.
Crown Copyright  2011 Published by Elsevier Ltd. All rights reserved.1. Introduction
Microtubules are a valuable target for cancer chemotherapy due
to their crucial role in vital cellular functions of tumor cells.
Tubulin inhibitors act by binding to some site on the tubulin di-
mers. These sites can be classiﬁed into three major categories
based on their respective tubulin-binding domains, which include
the ‘‘vinca alkaloid’’ domain, the ‘‘colchicine’’ domain, and the
‘‘paclitaxel’’ domain (Mollinedo and Gajate, 2003). Several clinical
agents are able to interact with microtubules, promoting either
microtubule disruption, such as combretastatin, vinca alkaloids,
and colchicine, or stabilization, such as paclitaxel and epothilone
B. Although these compounds exert opposite effects on microtu-
bules, both types of antitubulin agents share the common property
of suppressing microtubule dynamics. This interference with
microtubule dynamics results in metaphase arrest in dividing cells
(Mollinedo and Gajate, 2003; Jordan and Wilson, 1998).011 Published by Elsevier Ltd. All
ax: +55 85 3366 8333.
. Bezerra), c_pessoa@yahoo.Phenstatins are a novel family of tubulin polymerization inhib-
itors. The ﬁrst compound, phenstatin, was ﬁrst synthesized by
Pettit during research directed at the study of the structure–
activity relationship of combretastatins, where it was an unex-
pected product of the oxidation of combretastatin A-4 (CA-4)
(Pettit et al., 1998; Cushman et al., 1992; Liou et al., 2002, 2004).
Phenstatin showed strong cytotoxicity and antitubulin activity
similar to that of CA-4, and it has been extensively researched
(Alvarez et al., 2008, 2009, 2010). Therefore, a large number of
phenstatin derivatives have been reported.
(4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT)
(Fig. 1) is a phenstatin analog. PHT is a known tubulin inhibitor
that has potent cytotoxic activity (Frank and Tarbell, 1948; Liou
et al., 2002; Alvarez et al., 2009; Barbosa et al., 2009). Recently,
Magalhães et al. (2011) showed that PHT displays antitumor ef-
fects in vitro and in vivo, without substantial systemic toxicity.
On the other hand, the genotoxic/mutagenic activities of the com-
pounds belonging to the phenstatin family had remained unex-
plored. The present study aimed to evaluate the mutagenic
potential of PHT in human lymphocytes. The chromosome aberra-
tion (CA) analysis in different phases of the cell cycle (G1, G1/S
transition, and G2) and alkaline comet assay were carried out torights reserved.
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O
O
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Fig. 1. Chemical structure of (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)metha-
none (PHT).
H.I.F. Magalhães et al. / Toxicology in Vitro 25 (2011) 2048–2053 2049evaluate the clastogenic and DNA-damaging effects of PHT,
respectively.2. Material and methods
2.1. (4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT)
synthesis
The process of PHT synthesis was performed as described by
Magalhães et al. (2011). The reaction was carried out in a one-neck,
250 ml round-bottomed ﬂask ﬁtted with a condenser with drying
tube. Anhydrous dichloromethane (20 ml), 3,4,5-trimethoxybenzo-
ic acid (1.4 g, 6.6 mmol) and thionyl chloride (1.57 g, 13.2 mmol)
were added to the ﬂask. The mixture was reﬂuxed for 4 h, and after
cooling to room temperature, the solvent was removed with a ro-
tary evaporator. Dichloromethane (25 ml) was added to the ﬂask
and cooled to 0 C. With good stirring, anhydrous aluminum chlo-
ride (0.44 g, 3.3 mmol) and anisole (0.72 g, 6.6 mmol) were slowly
tapped into the reaction vessel, which required 10 min. After the
addition, the reaction mixture was stirred at room temperature
for 30 min and then allowed to decompose by pouring ice-cold
hydrochloric acid (20 ml) into the ﬂask. After extraction with
dichloromethane and washing with cold sodium bicarbonate solu-
tion and water, the organic layer was removed using a rotary evap-
orator. The residue was puriﬁed by ﬂash chromatography using an
eluent of 5:1 hexane:ethyl acetate. A colorless crystalline solid was
obtained. EI-MS: 303.2026[M+1], Yield = 80%, m.p. = 67–68 C.
2.2. Human lymphocyte culture
The primary culture was obtained by a standard protocol using
Ficoll gradient. In addition, phytohemagglutinin (PHA) was used as
a mitogen to trigger cell division in T-lymphocytes. Peripheral
blood was collected from four normal, healthy donors, two women
and two men, aged 19–30 years, with no history of smoking/drink-
ing or chronic drug use. Venous blood (10 ml) was collected from
each donor into heparinized vials. Lymphocytes were isolated by
Ficoll density gradient (Histopaque-1077; Sigma Diagnostics, Inc.,
St. Louis). The culture medium consisted of RPMI 1640 supple-
mented with 20% fetal bovine serum, phytohemagglutinin (ﬁnal
concentration: 2%), 2 mM glutamine, 100 U/ml penicillin, and
100 lg/ml streptomycin at 37 C with 5% CO2 (Berthol, 1981;
Hutchins and Steel, 1983; Brown and Lawce, 1997).
For all experiments, cell viability was performed by Trypan Blue
assay. Over 90% of the cells were viable at the beginning of the
culture.
2.3. Cytotoxic assay
The growth of cultured human lymphocytes was determined by
the Alamar blue assay (Ahmed et al., 1994). For all experiments,
cells were seeded in 96-well plates (0.3  106 cells/ml, in 100 llof medium). After 24 h, the test substance (0.09–5 lg/ml), dis-
solved in 1% DMSO, was added to each well (using the HTS –
high-throughput screening – Biomek 3000 – Beckman Coulter,
Inc. Fullerton, CA, USA) and incubated for 72 h. Doxorubicin (Sigma
Aldrich Co. St. Louis, MO, USA) was used as a positive control.
Twenty-four hours before the end of incubation, 10 ll of stock
solution (0.312 mg/ml) of Alamar Blue (Resazurin, Sigma Aldrich
Co. St. Louis, MO, USA) was added to each well. The absorbance
was measured using a multiplate reader (DTX 880 Multimode
Detector, Beckman Coulter), and the drug effect was quantiﬁed
as the percentage of control absorbance at 570 and 595 nm. The
absorbance of Alamar Blue in culture medium is measured at a
higher wavelength and lower wavelength. The absorbance of the
medium is also measured at the higher and lower wavelengths.
The absorbance of the medium alone is subtracted from the absor-
bance of medium plus Alamar Blue at the higher wavelength. This
value is called AOHW. The absorbance of the medium alone is sub-
tracted from the absorbance of medium plus Alamar Blue at the
lower wavelength. This value is called AOLW. A correction factor
R0 can be calculated from AOHW and AOLW, where R0 = AOLW/
AOHW. The percent Alamar Blue reduced is then expressed as fol-
lows: % reduced = ALW  (AHW  R0)  100.
2.4. Alkaline comet assay
Cultured human lymphocytes were plated at a concentration of
0.3  106 cells/ml and incubated for 24 h with different concentra-
tions of PHT (0.25, 0.5, 1.0, 2.0, and 4.0 lM) and then mixed with
low-melting point agarose. Doxorubicin (0.5 lM) was used as a po-
sitive control. The alkaline version of the comet assay (single cell gel
electrophoresis) was performed as described by Singh et al. (1988)
with minor modiﬁcations (Hartmann and Speit, 1997). Slides were
prepared in duplicate, and 100 cells were screened per sample (50
cells from each duplicate slide), using a ﬂuorescence microscope
(Zeiss) equippedwith a 515–560 nm excitation ﬁlter, a 590 nm bar-
rier ﬁlter, and a 40 objective. Cells were scored visually according
to tail length into ﬁve classes: (1) class 0: undamaged,without a tail;
(2) class 1: with a tail shorter than the diameter of the head (nu-
cleus); (3) class 2: with a tail length 1–2 the diameter of the head;
(4) class 3: with a tail longer than 2 the diameter of the head; (5)
class 4: comets with no heads. Two different but complementary
parameters were employed: Damage index (DI) and damage fre-
quency (DF). DI is based on migration length and on the amount of
DNA in the tail, and it is considered a sensitiveDNAmeasure. A value
(DI) was assigned to each comet according to its class, using the for-
mula: DI = (0  n0) + (1  n1) + (2  n2) + (3  n3) + (4  n4), where
n = number of cells in each class analyzed. The damage index ranged
from 0 (completely undamaged: 100 cells  0) to 400 (with maxi-
mum damage: 100 cells  4). On the other hand, DF represents the
percentage of cells (tailed cells) with DNA damage (Speit and Hart-
mann, 1999).
2.5. Chromosome aberration assay
Naturally synchronized human peripheral blood lymphocytes
were used with more than 95% of cells in the G0 phase (Bender
et al., 1988; Wojcik et al., 1996). Short-term lymphocyte cultures,
at a concentration of 0.3  106 cells/ml, were initiated according
to a standard protocol (Preston et al., 1987). PHT was studied at
ﬁve concentrations (0.25, 0.5, 1.0, 2.0, and 4.0 lM) at different
phases of the cell cycle based on the protocol described by Caval-
canti et al. (2008) with minor modiﬁcations. Doxorubicin
(0.5 lM) was used as a positive control. All experimental protocols
were performed in the presence or absence of colchicine. In the
experimental procedures adopted, when PHT was added after
24 h, cells in both G1 and S stages were exposed, while it can be
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Fig. 2. Concentration–response curve showing the cytotoxic activity of
(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT, d) in human lym-
phocytes growth analyzed by Alamar blue after 72 h of incubation. Data are
presented as mean ± S.E.M. from three independent experiments performed in
duplicate. The IC50 values and 95% conﬁdence intervals also are showed. Doxoru-
bicin (j) was used as a positive control. Negative control was performed in the
presence of vehicle used for suspension of tested substance.
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were exposed. When PHT was added in same time of PHA stimula-
tion (in begin of the culture, 0 h) cells were exposed in G1 stage. In
order to obtain a sufﬁcient number of analyzable metaphases, col-
chicine was added at a ﬁnal concentration of 0.0016%, 2 h prior to
harvesting. The cells were harvested by centrifugation and treated
with 0.075 M KCl at 37 C for 20 min. The cells were then centri-
fuged and ﬁxed in 1:3 (v/v) acetic acid:methanol. Finally, slides
were prepared, air-dried and stained with 3% Giemsa solution
(pH 6.8) for 8 min (Moorhead et al., 1960).
Slides were analyzed with a light microscope, and structural
and numerical CAs were examined in metaphases from the PHT-
treated cultures and from the respective controls. The frequency
of CAs (in 100 metaphases per culture) and the mitotic index
(MI, number of metaphases per 2.000 lymphocytes per culture)
were determined.
2.6. Statistical analysis
The differences between experimental groups were compared
by one-way analysis of variance (ANOVA) followed by Tukey’s test.
All analyses were performed using the Graphpad program (Intui-
tive Software for Science, San Diego, CA).3. Results
3.1. Cytotoxic effect in human lymphocytes
The Alamar Blue assay was performed to evaluate the effect of
PHT in human lymphocytes. Based on data collected from three
independent experiments carried out in duplicate, the IC50 values
obtained in human lymphocytes for PHT and doxorubicin were
5.68 (4.17–7.28) and 1.78 (0.96–3.31) lM, respectively, after 72 h
of incubation (Fig. 2).
All subsequent experiments were conducted in human lympho-
cytes at concentrations of 0.25, 0.5, 1.0, 2.0, and 4.0 lM.
3.2. DNA-damaging effects in human lymphocytes
The alkaline comet assay was used to evaluate induction of sin-
gle-strand and double-strand breaks (DSB) in human lymphocytes.
Fig. 3 shows the effect of PHT on the damage index and on damage
frequency, as measured by effects on DNA. At 2.0 and 4.0 lM, PHT
clearly produced a signiﬁcant increase in damage index and dam-
age frequency as compared to the control groups. In addition, this
increase in damage score occurred in a dose-related manner.
3.3. Clastogenic effects in human lymphocytes
CA analysis was performed to evaluate the clastogenic effects of
PHT during G1 (Table 1), G1/S transition (Table 2), and G2 (Table 3)
of the cell cycle. In addition, the experimental protocols of the CAs
were performed in the presence or absence of colchicine to evalu-
ate the action of PHT in the mitotic phase. PHT was clastogenic in
all phases of the cell cycle in the presence or absence of colchicine.
Chromatid gaps and chromatid breaks were the most frequent CAs.
No signiﬁcant induction of endoreduplication or polyploidy was
observed.
In protocol with colchicine, the cytotoxic, as observed by MI de-
crease, and chromosomal abnormalities effects were observed in
lymphocytes in all cell cycle phases analyzed. On the other hand,
only in G1 phase, PHT was active in all concentrations tested. This
implies that G1 phase seen to be more sensitive to PHT effects.
Interestingly, PHT induced an increase in mitotic index in experi-
mental protocols without colchicine, corroborating its action asan antitubulin agent. The most expressive was found in G2 phase,
where the MI of control was 0.2%. In the presence of PHT (0.25,
0.5, 1.0, 2.0 or 4.0 lM), the MI were 1.9%, 3.2%, 3.5%, 3.0%, and
2.5%, respectively. PTH was able to increase the MI from 0.2% to
3.5 % (Table 3).4. Discussion
The interaction of tubulin inhibitors with microtubules results
in alteration of microtubule dynamics, which may lead to damage
of the mitotic spindle (Kanthou et al., 2004; Vitale et al., 2007).
Herein, the mutagenic potential of a representative of the phenst-
atin family, tubulin inhibitors, was evaluated for the ﬁrst time.
Ours results suggesting that PHT induces DNA damage and ex-
erts clastogenic effects in human lymphocytes. Although this geno-
toxic effect of PHT could be biologically relevant as an alternative
strategy for killing tumor cells, this effect needs to be extensively
evaluated to assess the safety of this chemical.
The effects of PHT on DNA integrity were evaluated using the
alkaline comet assay in peripheral blood lymphocytes. The comet
assay is a genotoxicity test widely applied, both in vivo and
in vitro, to different organs and tissues (Hartmann et al., 2003;
Collins, 2004). PHT treatments increased the levels of DNA damage.
Antitubulin agents have been previously tested in the comet as-
say in vitro and in vivo, and they display a variety of genotoxic re-
sults. Some studies showed that paclitaxel (Lee et al., 2003),
colchicine (Villani et al., 2010), or vincristine (Recio et al., 2010)
do not induce DNA damage (negative results in the comet assay).
The lack of detectable DNA damage using the comet assay is con-
sistent with tubulin, rather than DNA, as a primary cellular target
of these agents (Recio et al., 2010). On the contrary, Branham
et al. (2004) showed that the chemotherapeutic drug paclitaxel in-
duces DNA damage (detected by the comet assay) in peripheral
blood lymphocytes. This effect seems to be inﬂuenced by drug con-
centration, time of exposure, and the mechanism of DNA repair.
However, the exact mechanism by which antitubulin agents in-
duce DNA damage is not clear.
CAs and MI were determined in cultured human lymphocytes
treated with PHT during different cell cycle times: G1 (Table 1),
G1/S (Table 2), and G2 (Table 3). The experimental protocols of
CA analysis were performed in the presence or absence of colchi-
cine to evaluate the action of the PHT in the mitotic phase. In pro-
tocol with colchicine, the cytotoxic, as observed by MI decrease,
and chromosomal abnormalities effects were observed in
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Fig. 3. Effect of (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT) on cell damage index (A) and on cell damage frequency (B) in human lymphocytes,
determined by the alkaline comet assay after 24 h incubation. Data are presented as means ± S.E.M. from two independent experiments performed in triplicate. Doxorubicin
(DOX, 0.5 lM) was used as a positive control. a, P < 0.01 compared to control by one-way ANOVA followed by Tukey’s test.
Table 1
Chromosome aberrations (CAs) and mitotic index (MI) in cultured human lymphocytes treated with (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT) during the G1
phase of the cell cycle.
Treatment Concentration (lM) MI (%) CAs Polyp End
Gaps Breaks Total
Protocol I (with colchicine)
Control – 4.6 1 0 1 1 0
Doxorubicin 0.5 2.0a 4 7 11a 3 0
PHT 0.25 4.0a 3 1 4a 2 0
0.5 3.8a 3 1 4a 2 0
1.0 3.0a 2 2 4a 1 1
2.0 2.9a 3 2 5a 2 0
4.0 2.8a 4 4 8a 2 0
Protocol II (without colchicine)
Control – 0.2 0 0 0 0 0
Doxorubicin 0.5 0 0 0 0 0 0
PHT 0.25 1.0a 3 1 4a 0 0
0.5 2.2a 4 2 6a 0 1
1.0 2.3a 3 2 5a 2 0
2.0 1.8a 2 2 4a 0 0
4.0 0.6a 3 3 6a 1 2
Polyp: polyploid cells; End: endoreduplication; Slides were analyzed with a light microscope, and structural (chromosome/chromatid gaps and breaks) and numerical CAs
were examined in metaphases. The frequency of CAs was determined in 100 metaphases per culture and MI was determined by the number of metaphases per 2000
lymphocytes per culture. Doxorubicin was used as a positive control.
a P < 0.01 compared to control by one-way ANOVA followed by Tukey’s test.
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only in G1 phase, PHT was active in all concentrations tested. This
implies that G1 phase seen to be more sensitive to PHT effects. The
cytotoxicity observed in the present study corroborate the ﬁndings
of previous works, where PHT was shown to be cytotoxic in tumor
cell lines (Liou et al., 2002; Alvarez et al., 2009; Barbosa et al.,
2009; Magalhães et al., 2011). Interestingly, like others tubulin
inhibitors, PHT induced an increase in mitotic index in experimen-
tal protocols without colchicine. The accumulation of metaphase
cells in cultures lacking colchicine corroborates its action as an
antitubulin agent.
Although antitubulin agents do not directly interact with DNA,
they exert aneugenic, clastogenic and recombinagenic effects (Lee
et al., 2003; Digue et al., 1999; Rodríguez-Arnaiz et al., 2004). In
fact, a considerable increase in the frequency of CAs was found in
cells exposed to PHT in all phases of the cell cycle analyzed, where
chromatid gaps and chromatid breaks were the most frequent CAs.
Chromosome and/or chromatid breaks and gaps were scored as
chromosome aberrations in this study. Some studies showed that
counting gaps can be subjective, and they may be the result of
technical artifacts, of variability within the same culture, and of
variability in the culture conditions (Schinzel and Schmid, 1976;
Brogger, 1982). However, Paz-y-Mino et al. (2002) obtained resultsindicating that gaps are indicative of DNA damage, which supports
their inclusion in the analysis of CAs.
Surprisingly, polyploid and endoreduplicated cells were not in-
creased with any of the concentrations tested, suggesting that PHT
does not affect mitotic spindle formation. This effect may only be
observed at high concentrations.
Although inhibition of mitotic progression correlates with geno-
toxicity of antitubulin agents, the pathways involved remain un-
clear (Mollinedo and Gajate, 2003). Paclitaxel was found to be a
strong in vitro aneugenic drug in human normal cells at therapeutic
doses (Digue et al., 1999). In another report, this agent produced
both structural chromosome aberrations through clastogenic activ-
ities andmitotic recombination through DNA interactions in the w/
w+ somatic assay in D. melanogaster (Rodríguez-Arnaiz et al.,
2004). Vincristine induced genotoxicity and bone marrow toxicity
in mice and rats based on evaluations of micronucleus assay data
reported previously (Witt et al., 2008). Additionally, vincristine-
induced chromosomal damage is primarily numerical in nature
(chromosome loss) and results from impaired microtubule
vassembly and subsequent chromosome malsegregation and loss
(Eastmond and Tucker, 1989).
In conclusion, the present study indicates that PHT produces
DNA-damage and clastogenic effects in human lymphocytes. These
Table 3
Chromosome aberrations (CAs) and mitotic index (MI) in cultured human lymphocytes treated with (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT) during the G2
phase of the cell cycle.
Treatment Concentration (lM) MI (%) CAs Polyp End
Gaps Breaks Total
Protocol I (with colchicine)
Control – 5.0 2 0 2 1 0
Doxorubicin 0.5 4.0a 13 7 20a 4a 4a
PHT 0.25 4.9 2 1 3 1 0
0.5 4.7 1 1 2 0 0
1.0 4.5a 0 1 1 1 1
2.0 4.2a 2 2 4 1 0
4.0 4.0a 4 4 8a 2 0
Protocol II (without colchicine)
Control – 0.2 0 0 0 0 0
Doxorubicin 0.5 0 0 0 0 0 0
PHT 0.25 1.9a 2 0 2 0 0
0.5 3.2a 2 0 2 0 0
1.0 3.5a 1 1 0 0 0
2.0 3.0a 1 3 4a 0 0
4.0 2.5a 5 5 10a 0 0
Polyp: polyploid cells; End: endoreduplication; Slides were analyzed with a light microscope, and structural (chromosome/chromatid gaps and breaks) and numerical CAs
were examined in metaphases. The frequency of CAs was determined in 100 metaphases per culture and the MI was determined by the number of metaphases per 2000
lymphocytes per culture. Doxorubicin was used as a positive control.
a P < 0.01 compared to control by one-way ANOVA followed by Tukey’s test.
Table 2
Chromosome aberrations (CAs) and mitotic index (MI) in cultured human lymphocytes treated with (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone (PHT) during G1/S
transition of the cell cycle.
Treatment Concentration (lM) MI (%) CAs Polyp End
Gaps Breaks Total
Protocol I (with colchicine)
Control – 4.4 2 0 2 0 0
Doxorubicin 0.5 2.5a 10 5 15a 2 1
PHT 0.25 4.2 2 0 2 2 0
0.5 4.0 2 1 3 1 1
1.0 3.4a 4 2 6a 1 1
2.0 3.2a 3 2 9a 1 0
4.0 3.0a 4 3 7a 2 1
Protocol II (without colchicine)
Control – 0.2 0 0 0 0 0
Doxorubicin 0.5 0 0 0 0 0 0
PHT 0.25 1.6a 1 0 1 1 0
0.5 2.8a 1 0 1 0 0
1.0 2.7a 1 3 4a 1 0
2.0 1.9a 2 3 5a 0 1
4.0 0.8a 1 4 5a 1 0
Polyp: polyploid cells; End: endoreduplication; Slides were analyzed with a light microscope, and structural (chromosome/chromatid gaps and breaks) and numerical CAs
were examined in metaphases. The frequency of CAs was determined in 100 metaphases per culture and the MI was determined by the number of metaphases per 2000
lymphocytes per culture. Doxorubicin was used as a positive control.
a P < 0.01 compared to control by one-way ANOVA followed by Tukey’s test.
2052 H.I.F. Magalhães et al. / Toxicology in Vitro 25 (2011) 2048–2053data indicate the mutagenic potential of phenstatin compounds,
known to be tubulin inhibitors. Further studies are needed to iden-
tify the molecular mechanism underlying PHT-induced genotoxic
effects.
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